Ypsomed Holding AG (CH:YPSN)
:YPSN
Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF307.50
-CHF5.00(-1.41%)
At close: 4:00 PM EST
CHF307.50
-CHF5.00(-1.41%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF441.50
Previous CloseN/A
Volume2.70K
Average Volume (3M)17.31K
Market Cap
CHF4.83B
Enterprise ValueCHF4.84B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)17.3
Beta0.68
Next Earnings
Nov 18, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,649,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF342.00Price Target Upside11.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.51
Revenue Forecast (FY)CHF710.41M
Bulls Say, Bears Say
Bulls Say
Stable, Recurring Delivery Systems Revenue BaseDelivery Systems provide a durable, high-share revenue stream (over 80% of group), backed by customer partnerships, repeat manufacturing and consumables. A diversified client base (>130 customers, top customer <15%) increases revenue visibility and reduces concentration risk over the medium term.
Differentiated Product Platforms And IP LongevityLaunches of recyclable platforms and new device families create technical differentiation and longer patent/IP tails, enhancing customer stickiness. Platforms that meet ecodesign and regulatory trends can secure multi-decade revenue streams from large pharma partners and support premium pricing and repeat programs.
Operational Execution: Faster Service And Strong Capital ReturnsReducing time‑to‑clinic materially shortens customer development cycles, making Ypsomed more attractive to biotech clients and accelerating contract revenue realization. Coupled with ~20% ROCE, this indicates capital investments generate high returns, supporting scalable, profitable growth over years.
Bears Say
Persistent Negative Free Cash FlowSustained negative free cash flow indicates ongoing heavy investment and/or working‑capital demands that consume cash despite strong operating cash generation. Over the medium term this constrains financial flexibility, may limit buybacks/dividends, and requires careful funding or customer co‑financing to avoid balance sheet strain.
Recent Revenue Contraction And Near‑term Revenue CutsA top‑line decline and planned removal of contract manufacturing revenue create a lower near‑term revenue baseline. Even if EBIT impact is modest, lost volume reduces operational scale and can pressure absorption of fixed costs, making growth and margin targets harder to sustain without offsetting new wins.
Ramp‑up, Stranded Costs And Sizeable Growth CapexLarge factory expansions and tooling programs produce temporary ramp‑up inefficiencies and stranded costs that can depress margins and cash flow while capacity comes online. The multi‑year CHF 1.3bn capex plan, even with customer co‑financing, raises execution and funding risk over the medium term.
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF441.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF4.83B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 18, 2026 which is in 160 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF3.455 which represents an annual dividend yield of 0.67%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.25.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,649,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.33%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG is a Swiss medical technology firm specializing in the development, manufacturing, and global distribution of advanced injection and infusion systems, primarily serving pharmaceutical and biotechnology companies. The enterprise operates through two primary segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment, identified by the YDS brand, provides a diverse range of sophisticated self-injection and infusion devices, including pen, auto, patch, and wearable injectors, alongside other smart medical solutions. Conversely, the Ypsomed Diabetes Care segment, recognized by its mylife brand, offers crucial products for diabetes management, encompassing insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, and a range of complementary accessories. Additionally, Ypsomed provides precision-turned components, contract manufacturing, and various other services. Its market presence is established through collaborations with biotechnology and pharmaceutical partners, alongside its own distribution network and independent distributors. The company maintains a global presence, operating in Switzerland, across Europe, North America, and numerous other international regions. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF342.00
▲(11.22% Upside)
Technical Analysis
Options Prices
Currently, No data available
---